{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": "A30P",
        "variant_string_id": "SNCA A30P"
      },
      "assessments": [
        {
          "step": "1",
          "description": "Define the disease mechanism",
          "judgment": "Yes",
          "explanation": "The study links α-syn mutations (A30P, A53T, E46K) to familial Parkinson's disease, establishing a clear disease mechanism."
        },
        {
          "step": "2",
          "description": "Evaluate assay applicability",
          "judgment": "Yes",
          "explanation": "Membrane binding assays and cytosolic factor (lipid/ATP) interactions are directly relevant to α-syn's role in Parkinson's pathology."
        },
        {
          "step": "3",
          "description": "Evaluate assay validity",
          "judgment": "Yes",
          "explanation": "The study includes wild-type controls, mutant variants, and replicates (e.g., protease-sensitive factors mitigating A30P impairment)."
        },
        {
          "step": "4",
          "description": "Apply evidence to variant interpretation",
          "judgment": "PS3_supporting",
          "explanation": "The study shows A30P exhibits impaired membrane binding, but protease-sensitive factors mitigate this effect. No OddsPath calculation is provided, and the number of control variants is unspecified. Thus, the evidence is supportive but not definitive."
        }
      ]
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": "A53T",
        "variant_string_id": "SNCA A53T"
      },
      "assessments": [
        {
          "step": "1",
          "description": "Define the disease mechanism",
          "judgment": "Yes",
          "explanation": "The study links α-syn mutations (A30P, A53T, E46K) to familial Parkinson's disease, establishing a clear disease mechanism."
        },
        {
          "step": "2",
          "description": "Evaluate assay applicability",
          "judgment": "Yes",
          "explanation": "Membrane binding assays and cytosolic factor (lipid/ATP) interactions are directly relevant to α-syn's role in Parkinson's pathology."
        },
        {
          "step": "3",
          "description": "Evaluate assay validity",
          "judgment": "Yes",
          "explanation": "The study includes wild-type controls, mutant variants, and replicates (e.g., lipids and ATP enhancing A53T binding)."
        },
        {
          "step": "4",
          "description": "Apply evidence to variant interpretation",
          "judgment": "PS3_moderate",
          "explanation": "The study shows A53T exhibits enhanced membrane binding with lipids and ATP, indicating a clear functional impact. No OddsPath calculation is provided, but the effect size (enhanced binding) suggests moderate pathogenicity."
        }
      ]
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": "E46K",
        "variant_string_id": "SNCA E46K"
      },
      "assessments": [
        {
          "step": "1",
          "description": "Define the disease mechanism",
          "judgment": "Yes",
          "explanation": "The study links α-syn mutations (A30P, A53T, E46K) to familial Parkinson's disease, establishing a clear disease mechanism."
        },
        {
          "step": "2",
          "description": "Evaluate assay applicability",
          "judgment": "No",
          "explanation": "The abstract does not provide functional data for E46K. Only background mentions it as a mutation, but no specific assay results are reported."
        },
        {
          "step": "3",
          "description": "Evaluate assay validity",
          "judgment": "N/A",
          "explanation": "No functional assays or controls are reported for E46K."
        },
        {
          "step": "4",
          "description": "Apply evidence to variant interpretation",
          "judgment": "Excluded",
          "explanation": "No functional evidence is provided for E46K in the study, so it cannot be evaluated under the ACMG framework."
        }
      ]
    }
  ]
}